Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors PR Newswire SAN DIEGO, March 14, 2013 SAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Stephen L. Newman, M.D., to the company's board of directors. "We are very pleased to welcome Dr. Newman to our board of directors. His experience in the evolving sector of integrated delivery networks, significant healthcare operations experience, and clinical background will be an invaluable addition to our board as we seek to expand our portfolio of products for use within the hospital setting," stated Cam Garner, Chairman of Cadence. Dr. Newman served in positions of increasing responsibility with Tenet Healthcare Corporation (NYSE:THC), including as Vice Chairman from January 2012 until his retirement inJune 2012. Since joining Tenet in 1999, he also served as Corporate Chief Operating Officer and Executive Vice President of Tenet Healthcare Corporation, Chief Executive Officer of Tenet HealthSystem, California, and as Senior Vice President, Gulf States Region, of Tenet HealthSystem. Prior to joining Tenet, Dr.Newmanheld executive positions atColumbia/HCA, Inc., and served as Senior Vice President and Chief Medical Officer of Touro Infirmary inNew Orleans. Earlier in his career, Dr. Newman was an Associate Professor of Pediatrics and Medicine atWright State UniversitySchool of Medicine, and Director of Gastroenterology and Nutrition Support at Children's Medical Center inDayton, Ohio. Dr. Newman is currently a member of the Labor, Education and Healthcare Council of the Federal Reserve Bank of Atlanta, and a member of the Board of Directors of Optimer Pharmaceuticals, Inc. and Hansen Medical, Inc. He holds a bachelor's degree fromRutgers University, an M.B.A. fromTulane Universityand a medical degree from theUniversity of Tennessee. Dr. Newman completed his internship, residency and fellowship atEmory University School of Medicine, and has also completed the Advanced Management Program at the University of Pennsylvania's Wharton School of Business. About Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview." CADENCE^® and OFIRMEV® are registered trademarks of Cadence Pharmaceuticals, Inc. Contact: William R. LaRue Kelli France SVP & Chief Financial Officer Media Relations Cadence Pharmaceuticals, Inc. WCG Phone: 858-436-1400 Phone: 415-946-1076 SOURCE Cadence Pharmaceuticals, Inc. Website: http://www.cadencepharm.com
Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
Press spacebar to pause and continue. Press esc to stop.